Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
European Urology Open Science|October 10, 2022
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety ProfileIlaria Lucca, Laurent Derré, Valérie Cesson, et al.
Frontiers in Immunology|November 28, 2025
Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patientsWalther Brochier, Sylvain Nguyen, Valérie Cesson, et al.
European Urology Focus|July 21, 2017
The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysisIlaria Lucca, Patrice Jichlinski, Shahrokh F Shariat, et al.
Urologic Oncology|March 15, 2016
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomyHarun Fajkovic, Romain Mathieu, Ilaria Lucca, et al.
The Journal of Urology|November 28, 2015
Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal UreterThomas Seisen, Laurent Nison, Mezut Remzi, et al.
BJU International|March 5, 2016
Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional studyRomain Mathieu, Ilaria Lucca, Mihai D Vartolomei, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potentialLaurent Derré, Ilaria Lucca, Valérie Cesson, et al.
BJU International|June 7, 2014
Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patientsIlaria Lucca, Morgan Rouprêt, Luis Kluth, et al.
BJU International|March 8, 2024
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabineLuca Afferi, Martin Spahn, Stefanie Hayoz, et al.
World Journal of Urology|October 27, 2014
Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomyRomain Mathieu, Shahrokh F Shariat, Christian Seitz, et al.
Pageof 9